Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
Volume 0.28M
Average 0.21M
NERV Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Minerva Neurosciences, Inc.NASDAQ: NERV
Operating Expenses · Q2 FY2026 · quarter ended Jun 2026
Operating expenses growth accelerates
Q2 FY2026 operating expenses of $10.64M rose 215.4% year over year, ahead of the +117.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 36.2% from the prior quarter. Over 3 fiscal years it compounded at -15.7% a year.
Context
- Operating expenses increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +215.4% holds above the trailing-twelve-month pace of +117.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 15.1M USD
- Year-over-year change
- -30.9%
- 4-year CAGR
- -24.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.1M | -30.9% |
| FY2024 | 2024-12-31 | 21.85M | -5.5% |
| FY2023 | 2023-12-31 | 23.12M | -8.4% |
| FY2022 | 2022-12-31 | 25.23M | -44.4% |
| FY2021 | 2021-12-31 | 45.37M | — |
Operating Expenses vs competitors
How NERV compares with its peers on the latest reported figures
- NERV's LTM Jun 2026 operating expenses of $35.14M is the highest of the 4 companies compared; the peer median is $14.79M.
- Its year-over-year change of +117.4% is the highest of 4, against a peer median of -6.9%.
- Over three fiscal years its annual growth of -15.7% compares with a peer median of -17.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $35.14M | +117.4% | -15.7% | — | |
| LTM Mar 2026 | $28.98M | -43.4% | -24.8% | 3377.9% | |
| LTM Dec 2025 | $14.79M | -6.9% | -17.2% | — | |
NRXSNeurAxis, Inc. | LTM Mar 2026 | $10.92M | +7.6% | +23.4% | 254.9% |
| Peer median (excluding NERV) | $14.79M | -6.9% | -17.2% | 1816.4% | |
Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.04M | 14.65M | 12.71M | 11.9M | 5.76M |
| Selling, General & Admin | 13.33M | 10.58M | 10.41M | 9.95M | 9.34M |
| Operating Expenses | 45.37M | 25.23M | 23.12M | 21.85M | 15.1M |
| Depreciation & Amortization | 101.79K | 8.51K | 30.98K | 22.47K | 5.44K |
| EBITDA | (45.28M) | (24.69M) | (21.69M) | 6.02M | (293.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.37M) | (25.23M) | (23.12M) | (21.85M) | (15.1M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 16.52K | 556.95K | 1.44M | 1.27M | 948.12K |
| Interest Expense | 6.33M | 7.41M | 8.28M | 4.56M | 0 |
| Other Income / Expenses | (6.34M) | (6.88M) | (6.89M) | 23.29M | (278.32M) |
| Income Before Tax | (51.71M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.8M) | 0 | 0 | 0 | 0 |
| Net Income | (49.91M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| EPS (Diluted) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| Weighted Avg Shares | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
| Weighted Avg Shares (Diluted) | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
Minerva Neurosciences, Inc.
NASDAQ:NERV
Intrinsic Alpha fair value
Locked
Current Price
$2.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.